Our response to COVID-19
The Meiji Group is responding to COVID-19 on multiple fronts which include supplying antigen test kits and developing inactivated vaccines and therapeutic agents. Our inactivated vaccine KD-414, currently in development, utilizes knowledge we have accumulated over many years in the vaccine field. We started clinical trials in March 2021, and obtained results in September that showed a certain level of efficacy and a high level of safety. We are now expediting the supply of this vaccine by bringing forward the target date for commercial release. Read more about our ongoing efforts at the link below.Countermeasures against Emerging and Re-emerging Infectious Diseases (PDF: 401KB)
Areas of Expertise
Inactivated quadrivalent split (HA) seasonal influenza vaccine
Adsorbed Diphtheria-purified Pertussis-Tetanus-inactivated polio (Sabin strain) Combined vaccine
Freeze-dried, Cell Culture-Derived Japanese Encephalitis Vaccine (Inactivated)
Recombinant adsorbed Hepatitis B Vaccine (yeast-derived)
Freeze-dried Inactivated Tissue Culture Hepatitis A Vaccine
New Vaccines for Emerging Infectious Diseases
Dengue fever is a mosquito-borne viral infection that can be fatal. Half the world's population is at risk, mainly in tropical and subtropical zones. Meiji Group company KM Biologics is developing a Dengue vaccine that has passed Phase I clinical trials. Unlike existing vaccines, the antibody is proving 100% effective at neutralizing all four Dengue serotypes with a single dose. The company is preparing for Phase II trials.
Find out more from our Wellness Stories
COVID-19: Hope for an Inactivated Vaccine
Read how pharmaceutical firms like Meiji Group are working to widen the range of available vaccine types for COVID-19.